March 23, 2018 03:46 AM EDT
Financing

Mor­phoSys files for $150M IPO to fu­el its hope­ful DL­B­CL drug launch

Brittany Meiling

Mor­phoSys, a pub­lic com­pa­ny in Ger­many, is shoot­ing for a dual list­ing of its shares, hop­ing to raise $150 mil­lion by head­ing to the Nas­daq …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

Lil­ly to buy non-opi­oid pain biotech SiteOne for up to $1B

RFK Jr. ends an­nu­al Covid vac­cine rec­om­men­da­tions for kids, preg­nant women

In­vestors pump $130M in­to pro­tein de­grad­er start­up Gly­co­Era

Prothena’s amy­loi­do­sis drug flops again, spend­ing and staff cuts are on the way

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times